1. Home
  2. JSPR vs PGEN Comparison

JSPR vs PGEN Comparison

Compare JSPR & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$1.76

Market Cap

48.1M

Sector

Health Care

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.16

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JSPR
PGEN
Founded
2018
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.1M
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JSPR
PGEN
Price
$1.76
$4.16
Analyst Decision
Buy
Buy
Analyst Count
11
5
Target Price
$21.44
$7.67
AVG Volume (30 Days)
4.0M
4.8M
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,309,000.00
Revenue This Year
N/A
$342.78
Revenue Next Year
N/A
$478.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
59.20
52 Week Low
$1.39
$0.69
52 Week High
$22.99
$5.23

Technical Indicators

Market Signals
Indicator
JSPR
PGEN
Relative Strength Index (RSI) 47.03 55.67
Support Level $1.61 $3.96
Resistance Level $1.96 $4.54
Average True Range (ATR) 0.12 0.28
MACD 0.02 0.06
Stochastic Oscillator 46.25 66.07

Price Performance

Historical Comparison
JSPR
PGEN

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: